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 Introduction 
 Upon binding of their cognate ligand, TNF receptor superfamily 
(TNFRSF) members transmit signals via their cytoplasmic do-
mains. Several TNF receptors bear death domains (DD) that al-
low them to directly promote apoptotic cell death. Activation of 
the TNFRSF receptors, such Fas or TNF-related apoptosis-induc-
ing ligand (TRAIL) – R2 ( Tartaglia et al., 1993 ), allows the bind-
ing of FADD in a DD – DD interaction, which initiates apoptotic 
signaling by the recruitment and activation of caspase 8 or 10 by 
oligomerization. TNF-R1 – induced activation of caspase 8 or 10 
is less direct, involving recruitment of the DD-containing adaptor 
TRADD, followed by the formation of an internalized secondary 
complex which can bind FADD and caspase 8 to initiate the 
apoptotic program ( Micheau and Tschopp, 2003 ). 
 Despite its name, most tumor cells do not die when exposed 
to TNF  but must also be treated with inhibitors of translation or 
transcription, such as actinomycin D or cycloheximide. These 
agents are thought to sensitize cells to TNF  by preventing produc-
tion of survival proteins induced via NF-  B. Many of the TNFRSF 
members, including FN14, contain a consensus Tnf receptor-asso-
ciated factor (TRAF) binding motif ( Park et al., 1999 ;  Ye et al., 
1999 ) that recruits TRAFs to activate transcription factors includ-
ing NF-  B and AP1 ( Lee et al., 1997 ;  Yeh et al., 1997 ). 
 TRAF1 and TRAF2 were initially identifi ed in protein 
complexes that bound to the cytoplasmic domain of TNF-R2 
( Rothe et al., 1994 ), together with cellular inhibitor of apoptosis 
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ingly, still requires cIAP1 function. The loss of cIAP1 or TRAF2, 
but not cIAP2 or XIAP, preferentially sensitizes immortalized 
cells, but not primary cells, to killing by TNF  . In contrast, over-
expression of both cIAP1 and TRAF2 correlates with tumor cell 
resistance to TWEAK/TNF  -induced cell death. These results 
provide mechanistic insights into how the cIAP1 – TRAF2 com-
plex functions in tumor cells to inhibit apoptosis and how this 
complex can be physiologically regulated. 
 Results 
 FN14 is expressed by most tumor cell 
lines 
 To understand how endogenous cIAPs regulate TNFRSF signal-
ing, we used TNFSF ligands to screen for cell lines containing 
detectable levels of endogenous TNFSF receptors. To facilitate 
the screen, we generated TNFSF ligands as recombinant proteins 
tagged with the Fc portion of human IgG (Fig. S1A, available at 
http://www.jcb.org/cgi/content/full/jcb.200801010/DC1;  Bossen 
et al., 2006 ). These molecules are cross-linked via the Fc portion 
that promotes higher order aggregation of the corresponding re-
ceptors, closely mimicking engagement by membrane-bound li-
gands ( Holler et al., 2003 ). The Fc portion also facilitates reliable 
detection of these proteins by Western blot (Fig. S1 B) and allows 
for their simple purifi cation with protein A (Fig. S1 B, right) and 
for immunoprecipitation of interacting protein complexes (see 
results below). 
 We tested the purifi ed Fc ligands for specifi c binding to 
their cognate receptor using FlpIn stable cell lines inducibly ex-
pressing different TNFSF receptors and only observed binding 
when the ligand was added to cells in which expression of the 
corresponding cognate receptor was induced, i.e., CD27/CD70 
and FN14/TWEAK (Fig. S1 C). Satisfi ed with the specifi city of 
the ligands, we used them to screen a panel of tumor cell lines 
(including those from kidney, brain, colon, melanoma, breast, 
and ovarian cancers). Only one of the ligands, TWEAK, bound 
to a high proportion of the tumor cell lines examined ( Fig. 1 A , 
Fig. S1 D, and not depicted), suggesting that in culture, many 
tumor cells constitutively express the TWEAK receptor FN14. [ID]FIG1[/ID] 
 Some studies have suggested that TWEAK binds other re-
ceptors in addition to FN14 ( Polek et al., 2003 ;  Bover et al., 
2007 ). To confi rm that the signal caused by binding of TWEAK 
correlated with expression of FN14, we used a commercial an-
tibody against FN14. The specifi city of this FN14 antibody was 
demonstrated by fl ow cytometry using cells inducible for FN14 
expression ( Fig. 1 B ). Importantly, cell lines that bound TWEAK 
also stained strongly with the antibody to FN14 ( Fig. 1 C ). 
These results demonstrate that a large number of transformed 
cell lines of both human and mouse origin constitutively ex-
press the TWEAK receptor FN14. 
 TWEAK binding to FN14 recruits TRAF2 
and cIAP1 
 Because yeast two-hybrid screens suggested a potential interac-
tion between TRAF2 and FN14 ( Brown et al., 2003 ), we tested 
whether TRAF2 could interact with FN14 in vivo. Recombinant 
Fc-TWEAK successfully immunoprecipitated endogenous 
[AQ1]
1 (cIAP1) and 2 ( Rothe et al., 1995 ). However, another cellular 
IAP homologue, XIAP ( Duckett et al., 1996 ;  Listen et al., 1996 ; 
 Uren et al., 1996 ), became the focus of attention because it was 
shown to directly inhibit activated downstream caspases ( Deve-
raux et al., 1997 ) and the N-terminally processed form of initia-
tor caspase, caspase 9 ( Srinivasula et al., 2001 ), whereas neither 
cIAP1 nor cIAP2 can inhibit caspase activity at concentrations 
that are reached in vivo ( Tenev et al., 2005 ;  Eckelman and Sal-
vesen, 2006 ) 
 Although the function of cIAP1 has remained unclear for 
some time, recent studies have identifi ed genetic abnormalities 
in cIAP1 from patients with multiple myeloma that correlate 
with reduced cIAP1 protein levels and enhanced noncanonical 
NF-  B activity ( Annunziata et al., 2007 ;  Keats et al., 2007 ). 
Consistent with this work, it has recently been demonstrated 
that genetic deletion of cIAP1 in immortalized mouse embry-
onic fi broblasts (MEFs) causes constitutive noncanonical NF-
  B activity and sensitization to TNF  -induced apoptosis ( Vince 
et al., 2007 ), and loss of cIAP1 sensitizes cells to TNF  ( Gaither 
et al., 2007 ). Strikingly, synthetic IAP antagonists, or smac mi-
metics, which deplete both cIAP1 and 2 protein levels, also ac-
tivate NF-  B signaling and enhance TNF  death signaling ( Li 
et al., 2004 ;  Gaither et al., 2007 ;  Varfolomeev et al., 2007 ;  Vince 
et al., 2007 ). Therefore, although the intended target of Smac 
mimetics was XIAP, it appears that their ability to effectively 
inhibit cIAP1 and or cIAP2 plays a central role in tumor cell 
killing and that cIAP1 is a central player in regulating the sur-
vival and death signals initiated from TNF-R1 in tumor cells. 
 cIAP1 and 2 were identifi ed via their indirect binding to 
TNF-R2, but they are also present in the TNF-R1 complex ( Mi-
cheau and Tschopp, 2003 ;  Vince et al., 2007 ) and have the po-
tential to regulate the signaling from   17 TNF superfamily 
receptors that contain TRAF2 consensus binding sites. Despite 
this, it is still unknown which receptors cIAP1 does bind and 
how it might be physiologically regulated to control signaling 
from these receptors. 
 TNF-like weak inducer of apoptosis (TWEAK) is a mem-
ber of the TNF superfamily (TNFSF12) that engages a receptor 
termed FN14 (TNFRSF12A). FN14 has been shown to bind 
TRAF2 (and TRAFs 1, 3, and 5) in a yeast two-hybrid screen 
( Brown et al., 2003 ) and can initiate both canonical and nonca-
nonical NF-  B activation ( Saitoh et al., 2003 ). It is unknown 
how FN14 activates NF-  B, but physiological TWEAK/FN14 
signaling can inhibit cellular differentiation, promote angiogen-
esis, cytokine production, and cellular proliferation, and has 
been suggested to play a role in the wound response because of 
its induction in wounded tissues and organs ( Vince and Silke, 
2006 ;  Winkles et al., 2007 ). TWEAK also induces apoptosis in 
HT29 and KATO-III cells pretreated with IFN  and has growth-
suppressive effects on several cell types ( Felli et al., 2005 ; 
 Maecker et al., 2005 ). 
 In this paper, we show that binding of TWEAK to endoge-
nous FN14 recruits a complex containing both cIAP1 and TRAF2. 
This complex is subsequently recruited to a lysosomal compart-
ment where it is degraded. Consistent with lysosomal degrada-
tion, TWEAK-induced TRAF2 degradation is prevented by 
several different inhibitors of lysosomal function but, interest-
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gase that ubiquitylates RIP ( Lee et al., 2004 ), thereby promoting 
activation of canonical NF-  B ( Chen et al., 2006 ). Other studies 
suggest cIAP1 is the ubiquitin E3 ligase for RIP ( Park et al., 
2004 ) and for TRAF2 itself ( Li et al., 2002 ). Indeed, the most 
widely accepted model for cIAP1 function, based largely on 
overexpression data, states that cIAP1 ubiquitylates TRAF2 
causing its proteasomal degradation ( Li et al., 2002 ). A fol-
lowup study using primary B cells also showed that TRAF2 
degradation after stimulation with agonistic TNF-R2 antibodies 
did not occur in cIAP1 knockout cells ( Zhao et al., 2007 ), lend-
ing credence to this model. We therefore tested whether TWEAK 
induced TRAF2 degradation. OVCAR4, SKOV3, Kym1 ( Fig. 2 
A ), and transformed MEF cells ( Fig. 2 C and not depicted) were 
treated with TWEAK for 0 – 6 h and cellular levels of endoge-
nous cIAP1 and TRAF2 analyzed by Western blot ( Fig. 2, A and 
C ). [ID]FIG2[/ID] After 1 – 6 h of TWEAK addition, cellular levels of both 
TRAF2 and cIAP1 were reduced in all cell lines examined. 
 TWEAK/FN14 promotes cathepsin 
dependent lysosomal degradation of the 
cIAP1 – TRAF2 complex 
 Although we observed substantial degradation of TRAF2 and 
cIAP1 after TWEAK treatment, we were surprised that the 
degradation of TRAF2 and cIAP1 could not be blocked by 
preincubating cells with proteasome inhibitors such as MG132 
(Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
TRAF2 and cIAP1 in D645 glioma cells, whereas in the absence 
of TWEAK, no TRAF2 or cIAP1 was detected ( Fig. 1 D ). 
 To test whether cIAP1 binding to FN14 was indirectly medi-
ated through TRAF2, we transiently transfected cIAP1   C6 (a 
stable mutant of cIAP1 lacking the last six residues) and cIAP1 
  BIR1 constructs into D645 glioma cells and immunoprecipitated 
endogenous FN14 with Fc-TWEAK. Consistent with previous 
observations ( Samuel et al., 2006 ;  Varfolomeev et al., 2006 ), 
cIAP1 constructs that lacked a BIR1 domain were unable to bind 
endogenous TRAF2, whereas mutations to other regions of cIAP1 
did not affect the TRAF2 interaction (Fig. S1 E and not depicted). 
As for endogenous cIAP1 ( Fig. 1 D ), transfected cIAP1   C6 
could be immunoprecipitated by Fc-TWEAK ( Fig. 1 E ), whereas 
  BIR1 cIAP1 could not be detected under the same conditions, 
even though endogenous TRAF2 was immunoprecipitated ( Fig. 1 
E ). Similarly, when vesicular stomatitis virus (VSV) – tagged FN14 
was induced and immunoprecipitated with anti-VSV in the pres-
ence of TWEAK, cIAP1   C6 could be detected, whereas neither 
  BIR1 cIAP1 nor   BIR1 cIAP1   C6 associated with FN14 (Fig. 
S1 F). These results strongly suggest that endogenous cIAP1 binds 
indirectly to FN14 through its association with TRAF2. 
 Signaling from FN14 induces the 
degradation of both TRAF2 and cIAP1 
 The role of TRAF2 and cIAP1 in TNFSF signaling is still un-
clear. Several studies suggest that TRAF2 is the ubiquitin E3 li-
 Figure 1.  TWEAK speciﬁ cally binds to endog-
enous FN14 in many tumor cell lines and cIAP1 
binds to FN14 via its TRAF2 binding domain. 
(A) Cells were harvested and incubated with 
Fc-CD70 or Fc-TWEAK, Tricolor-labeled anti-
Fc, and analyzed by ﬂ ow cytometry. (B) FN14 
antibody speciﬁ cally detects FN14. Stable Fl-
pIn T-REx 293 cells inducible for FN14 were 
induced with or without doxycycline overnight, 
stained with anti-FN14, and analyzed as in A. 
Controls were stained with secondary anti-
body alone. (C) Cell lines that bind TWEAK 
also stain with antibodies to FN14. Cells were 
harvested and stained with the FN14 antibody 
as in B. (D) D645 cells were harvested and 
then treated for 15 min at 37 ° C with or with-
out 2  μ g Fc-TWEAK. Cells were lysed and Fc-
TWEAK protein complexes precipitated with 
protein A beads and analyzed by Western 
blot. *, carryover signal from cIAP1 blot. (E) 
Binding of cIAP1 to FN14 is mediated by its 
association with TRAF2. D645 glioma cells 
were transfected with the indicated FLAG-
cIAP1 constructs, harvested, and then treated 
with Fc-TWEAK for 20 min at 37 ° C. Cells were 
lysed and Fc-TWEAK complexes precipitated 
and analyzed as in D. Molecular mass is indi-
cated in kD on the left of the autoradiograph. 
ROUGH GALLEY PROOF
JCB 4 of 15
 Because TWEAK did not induce proteasomal degradation 
of the cIAP1 – TRAF2 complex, we tested other protease inhibi-
tors. Cells preincubated with a protease inhibitor cocktail showed 
reduced TWEAK-mediated degradation of TRAF2 and a modest 
protecton of cIAP1 when serum was removed from the medium 
before addition of the inhibitor ( Fig. 2 D ). We therefore tested 
whether TWEAK-mediated TRAF2 and cIAP1 depletion was de-
pendent upon lysosomal function. Consistent with this hypothe-
sis, inhibitors of lysosomal function, such as chloroquine and 
ammonium chloride, prevented TWEAK-mediated TRAF2 deg-
radation, whereas ammonium chloride also substantially blocked 
TWEAK-mediated cIAP1 degradation, although not to the same 
extent as it blocked TRAF2 depletion ( Fig. 2, D and F ). 
 To further test a role for lysosomal proteases, we used 
specifi c protease inhibitors. The serine protease inhibitor 
AEBSF failed to block TWEAK-mediated cIAP1 – TRAF2 deg-
radation, whereas TLCK, which can inhibit both serine and cys-
teine proteases, partially blocked TWEAK-mediated TRAF2 
loss ( Fig. 2 E ). The cathepsin B inhibitor CA-074Me ( Fig. 2, E 
and F ) also provided protection against loss of both cIAP1 and 
TRAF2, implying that lysosomal cathepsins may be important 
for the degradation of this complex. Importantly, neither CA-
074Me nor the inhibitors of lysosomal function perturbed the 
proteasomal degradation pathway because they did not prevent 
the loss of cIAP1 induced by IAP antagonist (compound A) 
treatment ( Fig. 2 F ), which we have previously shown is protea-
somal dependent ( Vince et al., 2007 ). 
 Although endogenous TRAF2 and cIAP1 was diffi cult to 
detect by confocal microscopy, analysis of D645 cells tran-
siently transfected with FLAG-TRAF2 revealed that in unstim-
jcb.200801010/DC1) or PS341 ( Fig. 2 B ) before TWEAK 
stimulation, despite the fact that these inhibitors effi ciently 
blocked proteasome function, as indicated by enhanced levels 
of total cellular ubiquitylated proteins ( Fig. 2 B ). 
 TNF-R2 – induced TRAF2 degradation has been reported to 
occur by the E3 ubiquitin ligase activity of cIAP1 targeting it for 
proteasomal degradation ( Li et al., 2002 ). To examine the require-
ment of cIAP1 for TWEAK-induced TRAF2 loss, and vice versa, 
we used gene knockout transformed MEF cell lines and stimu-
lated endogenous FN14 with TWEAK. Although TWEAK stim-
ulation resulted in decreased levels of cIAP1 in wild-type MEFs, 
it was not degraded in TRAF2  /  knockout MEFs ( Fig. 2 C , 
left). TRAF2-mediated binding of cIAP1 to FN14 is therefore re-
quired for TWEAK-induced degradation of cIAP1. Consistent 
with previous studies, cIAP1 was required for the degradation of 
TRAF2 because TWEAK-stimulated TRAF2 depletion did not 
occur in cIAP1  /  MEFs ( Fig. 2 C , left). 
 To examine the requirement for cIAP1 in TRAF2 degra-
dation in greater detail, we performed further experiments 
where we lysed cells in Triton X-100 and examined the deter-
gent soluble and insoluble membrane fractions. Remarkably, 
TRAF2 disappeared from the Triton X-100 – soluble fraction in 
cIAP1 knockout cells as it did from wild-type cells ( Fig. 2 C , 
right; and Fig. S2 B). These two results suggest that TRAF2 
translocation to an insoluble compartment occurs in the absence 
of cIAP1 but its degradation requires the activity of cIAP1. This 
notion is consistent with previous reports demonstrating that 
TRAF2 relocalizes to a detergent-insoluble fraction and be-
comes degraded after signaling from other TNFSF receptors 
( Habelhah et al., 2004 ;  Wu et al., 2005 ). 
 Figure 2.  FN14 signaling decreases cellular cIAP1 and TRAF2 levels by lysosomal degradation. (A) OVCAR4, SKOV3, or Kym1 cells were treated with 
100 ng/ml Fc-TWEAK at 37 ° C for the indicated time, lysed, and analyzed by Western blot. (B) Proteasome inhibition does not block TWEAK-mediated 
cIAP1 or TRAF2 degradation. D645 cells were pretreated with or without 1  μ M PS341 for 2 h and then incubated with 100 ng/ml Fc-TWEAK for 4 h. The 
cells were lysed and analyzed by Western blot. (C) TRAF2 accumulates in the insoluble fraction in cIAP1 knockout MEF cells after TWEAK stimulation. The 
indicated MEF cell lines were treated with or without TWEAK for 6 h, and whole cell lysates (left) or Triton X-100 supernatant (SN) or pellet (P) fractions 
were analyzed by Western blot (right). (D) D645 cells were pretreated with a protease inhibitor cocktail (PI), 200  μ M chloroquine (Chlq), or 100 mM 
NH 4 Cl, with or without serum, and then stimulated with 100 ng/ml Fc-TWEAK for 4 h. Cells were lysed in 1% SDS and total cell lysate was analyzed by 
Western blot. (E) D645 cells were pretreated with 1  μ M PS341, 20  μ M CA-074Me, 40  μ M AEBSF, or 100  μ M TLCK for 2 h and then stimulated with 100 
ng/ml Fc-TWEAK for 4 h. Cell lysates were analyzed as in D. (F) D645 cells were pretreated for 2 h with 200  μ M chloroquine, 100 mM NH 4 Cl, or 20  μ M 
CA-074Me before stimulation with Fc-TWEAK (T) or the IAP antagonist compound A (A) for a further 6 h. Cell lysates were analyzed as in D. Molecular 
mass is indicated in kD on the left of the autoradiograph. 
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tent/full/jcb.200801010/DC1;  Grech et al., 2004 ;  Vince et al., 
2007 ), we hypothesized that TWEAK-mediated NF-  B signaling 
may be a direct result of the depletion of cIAP1 and TRAF2 and 
noncanonical in nature, despite the fact that degradation of cIAP1 
after TWEAK signaling is never complete. 
 To measure TWEAK-induced NF-  B activation, we created 
stable cell lines containing an NF-  B reporter, where expression 
of EGFP is driven by a promoter containing four NF-  B binding 
elements. As expected, NIH 3T3 cells bearing the NF-  B reporter 
showed strong NF-  B induction when stimulated with TNF  
( Fig. 3 A ). [ID]FIG3[/ID] TWEAK also induced a signifi cant NF-  B response, 
although this was slower and not as large as the TNF  response 
( Fig. 3 A ). TWEAK-induced NF-  B was not dependent upon au-
tocrine-produced TNF  because induction of NF   B could not 
be blocked by anti-TNF  (unpublished data). To investigate 
whether NF-  B was noncanonical, we examined processing of the 
NF-  B2 subunit from the p100 form to the activated, processed 
p52 form. In both OVCAR4 and KYM1 cell lines, processing of 
p100 to p52 became visible after 1 h of TWEAK stimulation ( Fig. 
3, B and C ) and correlated well with the TWEAK-induced loss of 
cIAP1 – TRAF2 ( Fig. 2 A ). Also consistent with noncanonical acti-
ulated cells, TRAF2 was exclusively cytosolic and did not 
overlap with the acidotropic lysosome marker lysotracker (Fig. 
S2, C and D). However upon stimulation with TWEAK ligand 
for 3 – 6 h, TRAF2 showed a signifi cant redistribution to punc-
tate vesicles (Fig. S2, C and E). TRAF2-containing vesicles 
were juxtaposed with lysotracker-stained compartments and of-
ten directly overlapped (Fig. S2 E), suggesting that TRAF2 deg-
radation occurs in the lysosome or in compartments that are in 
close association. It is probable that the Triton X-100 – insoluble 
fraction contains MVB/lysosomal membranes because the in-
hibitors NH 4 Cl and CA-074Me signifi cantly blocked degrada-
tion of TRAF2 and cIAP1 in the Triton X-100 – insoluble fraction 
(unpublished data). 
 TWEAK activates noncanonical NF-  B 
by depleting cIAP1 and TRAF2 
 TWEAK/FN14 signaling has previously been shown to activate 
both canonical and noncanonical NF-  B ( Saitoh et al., 2003 ). Be-
cause TRAF2 knockout B cells and either immortalized cIAP1 or 
TRAF2 knockout MEFs show constitutive activation of nonca-
nonical NF-  B (Fig. S3, available at http://www.jcb.org/cgi/con-
 Figure 3.  TWEAK-induced cIAP1 – TRAF2 loss 
activates noncanonical NF-  B. (A) An NIH 3T3 
cell clone stably transformed with a lentiviral 
NF-  B reporter vector was stimulated with Fc-
TNF or Fc-TWEAK for the indicated times. (B) 
Kym1 or OVCAR4 cells were stimulated with 
100 ng/ml Fc-TWEAK for the indicated times 
and analyzed by Western blot for p100 pro-
cessing to p52. (C) Kym1 or OVCAR4 cells 
were treated with or without Fc-TWEAK for 6 
h and lysates were analyzed by Western blot. 
(D) FN14-inducible FlpIn 293 cells infected 
with the lentiviral NF-  B reporter were tran-
siently transfected with the indicated constructs 
for 24 h. FN14 was induced overnight, the 
cells were treated with 100 ng/ml Fc-TWEAK 
for a further 24 h, and NF-  B activity was mea-
sured by ﬂ ow cytometry. Histograms are rep-
resentative of three independent experiments. 
(E) NH 4 Cl blocks TWEAK-induced noncanoni-
cal NF-  B. Cells were pretreated with NH 4 Cl, 
CA-074Me, or MG132 for 2 h and then 
treated with 100 ng/ml TWEAK for the indi-
cated times, lysed, and analyzed by Western 
blot. (F) Wild-type and knockout MEFs were 
treated with TWEAK for the indicated times, 
and lysates were analyzed as in E. Molecu-
lar mass is indicated in kD on the left of the 
autoradiograph. 
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 We observed that the levels of TNF  in the cell lysate of 
TWEAK-treated cell lines increased signifi cantly in all three 
cell types that are killed by TWEAK treatment alone ( Fig. 4, A 
and B ; and  Fig 5 A ) with a concomitant increase of TNF  re-
leased into the media supernatant ( Fig. 4 C ). [ID]FIG4[/ID]  [ID]FIG5[/ID] In contrast, cell 
lines that are not killed by TWEAK treatment alone did not pro-
duce TNF  when TWEAK was added (unpublished data), sug-
gesting that induction of TNF  is necessary for TWEAK to 
cause apoptosis. 
 To test whether activation of NF-  B by TWEAK/FN14 
was required for the enhanced TNF  production observed in 
TWEAK-sensitive cell lines, we created stable inducible nonde-
gradable I  B SR (I  B superrepressor) SKOV3 and OVCAR4 cell 
lines. Induction of I  B SR inhibited TWEAK-induced NF-  B ac-
tivity (Fig. S3 A) and signifi cantly reduced the TWEAK-depen-
dent increase in levels of cellular and secreted TNF  in both 
SKOV3 and OVCAR4 cells ( Fig. 4, D and E ). 
 Inhibition of TNF  signaling or caspase 8 
blocks TWEAK/FN14 cell death 
 Previous work with synthetic IAP antagonists ( Gaither et al., 
2007 ;  Varfolomeev et al., 2007 ;  Vince et al., 2007 ) and the data 
presented here with TWEAK demonstrate that either treatment 
vation of NF-  B, we observed that TWEAK treatment caused a 
remarkable stabilization of NIK ( Fig. 3, C and E ), which corre-
lated with processing of p100 to p52, but observed no change in 
NF-  B1 p105 processing ( Fig. 3, C and E ). 
 If TWEAK-induced loss of the cIAP1 – TRAF2 complex is 
required to activate the noncanonical pathway, then genetic loss 
of either cIAP1 or TRAF2 might also result in constitutive acti-
vation of this pathway. Consistent with this model and our pre-
vious observations ( Vince et al., 2007 ), MEFs deleted for either 
cIAP1 or TRAF2 showed elevated p52 levels and an increase in 
p52 localization to a nucleus-containing fraction (Fig. S3 A). In 
contrast, p50 localization was unaffected by loss of these genes 
and was predominantly present in the unprocessed p105 form in 
the cytoplasm (Fig. S3 A). 
 If depletion of the cIAP1 – TRAF2 complex is suffi cient to 
activate NF-  B, then overexpression of these two proteins should 
inhibit TWEAK/FN14-induced NF-  B activity. To test this hy-
pothesis, we used FN14-inducible NF-  B EGFP reporter cells in 
which maximal NF-  B activity was detected in cells that were si-
multaneously induced for FN14 expression and stimulated with 
TWEAK ligand and tested the effect of transiently transfecting 
cIAP1, TRAF2, or both ( Fig. 3 D ) in this system. Individual ex-
pression of either TRAF2 or cIAP1 failed to block TWEAK/
FN14-induced NF-  B activation ( Fig. 3 D ). However, the overex-
pression of both proteins together signifi cantly reduced the 
amount of NF-  B activation ( Fig. 3 D ). Importantly, this was de-
pendent on cIAP1 binding to TRAF2, because coexpression of 
TRAF2 with the   BIR1 cIAP1 mutant that is unable to bind 
TRAF2 (Fig. S1 E), was unable to inhibit FN14/TWEAK-in-
duced activation of NF-  B ( Fig. 3 D ). NIK stabilization and p100 
processing to p52 could be blocked by pretreatment of cells with 
NH 4 Cl but not by pretreatment with CA-074Me ( Fig. 3 E ). This 
suggests that relocalization to the lysosomal compartment is suf-
fi cient to trigger stabilization of NIK and subsequent processing 
of p100 rather than degradation in the lysosome per se. 
 Because TWEAK has been reported to activate the canon-
ical pathway, we also examined the effects of TWEAK and 
cIAP1 or TRAF2 loss on canonical signaling markers. Consis-
tent with previous observations ( Saitoh et al., 2003 ), we ob-
served TWEAK-induced rapid phosphorylation of I  B and p65. 
Loss of either cIAP1 or TRAF2 resulted in almost identical re-
sponses, with higher basal phosphorylation of I  B and p65 and 
a signifi cantly delayed TWEAK-induced increase ( Fig. 3 F ). 
This highlights that the cIAP1 – TRAF2 complex plays an im-
portant role in both NF-  B pathways induced by TWEAK. 
 TWEAK induces cell death through 
NF-  B – dependent induction of TNF  
 Tumor cell lines sensitive to synthetic IAP antagonists are killed 
through NF-  B – dependent autocrine production of TNF  
( Vince et al., 2007 ). Moreover, it has been described that 
TWEAK can kill Kym1 cells in a TNF  -dependent manner 
( Schneider et al., 1999 ), although how TWEAK stimulated 
TNF  in Kym1 cells remains unknown. We therefore asked 
whether TWEAK acted in a similar manner to synthetic IAP 
antagonists by causing an increase in the abundance of TNF  
driven through the activation of NF-  B. 
 Figure 4.  TWEAK-mediated NF-  B activation induces TNF   in TWEAK-
sensitive lines . Kym1 (A) or SKOV3 and OVCAR4 (B) cells were treated 
with Fc-TWEAK for 8 or 24 h, respectively and the amount of TNF  in 
cell lysates was measured by ELISA. (C) Supernatant from TWEAK-treated 
SKOV3 and OVCAR4 cells was collected and ﬁ ltered and TNF  was 
measured by ELISA. (D and E) SKOV3 and OVCAR4 cell lines containing 
inducible I  B SR were induced or not before Fc-TWEAK treatment for 24 h. 
The levels of TNF  in the cell lysate (D) or cell supernatant (E) was mea-
sured by ELISA. Error bars represent SEM from three to ﬁ ve independent 
experiments. 
ROUGH GALLEY PROOF
7 of 15FN14 SIGNALING SENSITIZES TUMOR CELLS TO TNF  • Vince et al. 
IKK1/2 complex with Geldanamycin is suffi cient to sensitize 
OVCAR4 and wild-type MEFs to TNF  (Fig. S4 E), presum-
ably by blocking NF-  B – induced transcription of prosurvival 
genes ( Wang et al., 2006 ). Remarkably, however, Geldanamy-
cin was able to block TWEAK-induced NF-  B (Fig. S4, C and 
D) and TWEAK-induced cell death of Kym1 and OVCAR4 
cells (Fig. S4 E). Moreover, although Geldanamycin-treated 
Kym1 cells showed reduced survival in long-term clonogenic 
growth assays, cells treated with TWEAK and Geldanamycin 
still showed clonogenic protection when compared with 
TWEAK treatment alone (Fig. S4 A). 
 TWEAK/FN14 signaling sensitizes cells 
to exogenously supplied TNF  
 Although TWEAK kills OVCAR4 and SKOV3 cells through 
induction of autocrine TNF  , it is known that, like most other 
cell types, these cells are resistant to TNF  treatment alone 
( Fig. 6 A ). [ID]FIG6[/ID] It has been recently shown that removal of cIAP1 by 
either synthetic IAP antagonists or in gene knockout MEFs sen-
sitizes these cells to TNF  killing ( Li et al., 2004 ;  Gaither et al., 
2007 ;  Vince et al., 2007 ). Therefore, we hypothesized that 
TWEAK not only induces TNF  but also sensitizes cells to 
TNF  -induced cell death through degradation of the cIAP1 –
 TRAF2 complex in a similar manner to synthetic IAP antago-
nists, which sensitize tumor cells to TNF  killing by depleting 
cIAP1, albeit in a mechanistically distinct fashion. 
results in an increase in TNF  , which is driven by NF-  B. Re-
markably, tumor cell lines that are killed by treatment with a 
synthetic IAP antagonist alone, such as OVCAR4, SKOV3, and 
Kym1 cells, ( Vince et al., 2007 ) are also killed by TWEAK. 
 TWEAK killing of sensitive cell lines was prevented by 
TNF  -blocking antibodies but not by TRAIL- or Fas ligand –
 neutralizing antibodies in both short-term ( Fig. 5 A ), and long-
term clonogenic survival assays (Fig. S4 A, available at http://www.
jcb.org/cgi/content/full/jcb.200801010/DC1), which is consis-
tent with a conserved mechanism of cell death between syn-
thetic IAP antagonist compounds and TWEAK. In addition, 
expression of the extracellular domain of TNF-R2 fused to a 
GPI-anchor (dnTNFR2), which is able to sequester and hence 
neutralize TNF  ( Vince et al., 2007 ), signifi cantly inhibited cell 
death caused by TWEAK ( Fig. 5 B ). In contrast, neither dnCD27 
nor dnTRAIL-R2 had any protective effect ( Fig. 5 B ). 
 Caspase 8 activity was necessary for TWEAK to induce 
apoptosis because Kym1 and SKOV3 cell lines inducibly ex-
pressing the caspase 8 inhibitor crmA were signifi cantly resis-
tant to TWEAK killing in both short-term ( Fig. 5 C ) and 
long-term clonogenic survival assays with Kym1 cells (Fig. 
S4 B). 
 To provide a nongenetic test that TWEAK-driven NF-  B 
was suffi cient to kill cells, we used Geldanamycin because it 
completely blocked TWEAK-induced NF-  B (Fig. S4 C). As 
has been shown before ( Wang et al., 2006 ), inhibiting the 
 Figure 5.  TWEAK-induced cell death is me-
diated by TNF  . (A) TWEAK-induced death 
is blocked by neutralizing TNF  antibodies. 
Kym1, SKOV3, and OVCAR4 cells were in-
cubated with Fc-TWEAK or Fc-CD27 (control) 
for 24 (Kym1) or 48 (SKOV3 and OVCAR4) 
h in the absence or presence of 10  μ g/ml of 
neutralizing antibodies against TNF  , FasL, 
or TRAIL. Cell death was measured by prop-
idium iodide staining and ﬂ ow cytometry. (B) 
Dominant-negative (dn) TNF receptor blocks 
TWEAK-induced cell death. Cells containing 
inducible dominant-negative GPI-anchored 
TNF-R2, CD27, or TRAILR2 receptors were in-
duced for 24 h before Fc-TWEAK treatment. 
Cell death was measured as in A. (C) TWEAK-
induced death is blocked by crmA. CrmA-in-
ducible Kym1 or SKOV3 cells were induced 
for 24 h before Fc-TWEAK or Fc-TNF  treat-
ment for 24 (Kym1) or 48 (SKOV3) h. Cell 
death was measured as in A. All errors bars 
represent SEM of at least three independent 
experiments. 
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treatment reduced cIAP1 and TRAF2 levels, whereas TNF  
treatment alone had no effect ( Fig. 6 C ). Consistent with the lack 
of cell death ( Fig. 6 A ), the individual treatments of TWEAK or 
TNF  did not alter caspase 8 cleavage ( Fig. 6 C ). In contrast, 
upon cotreatment of TWEAK with TNF  , processing of caspase 
8 into the p43/p41 forms and the active p18 subunit was observed 
within 3 h ( Fig. 6 C ) and correlated with the loss of cIAP1 –
 TRAF2 and the rapid death of these cells ( Fig. 6 A ). To allow a 
direct comparison with our synthetic IAP antagonist, we also in-
cubated D645 cells with compound A alone or compound A and 
TNF  . Treatment with compound A alone resulted in the rapid 
loss of cIAP1 but did not affect either TRAF2 or caspase 8 levels 
( Fig. 6 C ). Signifi cantly, cIAP1 loss alone was suffi cient to sensi-
tize D645 cells to TNF to a similar level as that of TWEAK-in-
duced depletion of the cIAP1 – TRAF2 complex ( Fig. 6 C ). 
 To test this hypothesis, exogenous TNF  was applied to 
TWEAK-sensitive (OVCAR4) and -resistant (D645 and MEF) 
cell lines alone or in combination with TWEAK for 24 h. Con-
sistent with an additional sensitizing role for TWEAK, OV-
CAR4 cells were killed by TWEAK/TNF  treatment far more 
effi ciently and rapidly than with TWEAK alone. Even more sig-
nifi cantly, D645 and MEF cells (among many other cell types; 
not depicted) were resistant to treatment with TWEAK or TNF  
alone but were extremely sensitive to combined TWEAK/TNF  
treatment ( Fig. 6, A and B ). Even a subset (2/12) of primary hu-
man tumor lines was signifi cantly sensitized to TNF  by 
TWEAK treatment ( Fig. 6 B ). 
 TWEAK sensitization to TNF  killing was examined fur-
ther by Western blot on the TWEAK (and TNF  )-resistant D645 
glioma cell line. As in TWEAK-sensitive cell lines, TWEAK 
 Figure 6.  TWEAK-induced cIAP1 – TRAF2 loss sensitizes transformed cells to TNF  - induced death.  (A) The indicated cell lines were treated with 100 ng/ml 
Fc-TWEAK and/or 100 ng/ml Fc-TNF  for 24 h, followed by propidium iodide staining and ﬂ ow cytometry to measure cell death. (B) TWEAK sensitizes 
primary human tumor lines D2234 and D2247 to TNF  . Cells from the indicated primary or established glioma cell lines were incubated in vitro with media 
and 100 ng/ml TNF  , 100 ng/ml TWEAK, or both for 72 h. Survival was assayed with CellTitre Glo and depicted by  “ bubble ” graphs. The areas of the 
circles and accompanying numbers denote net survival after each treatment, relative to untreated cells (set at 100%). (C) D645 cells were treated with the 
indicated combinations of Fc-TWEAK, 100 ng/ml Fc-TNF  , or 500 nM compound A for the indicated times and analyzed by Western blot. (D) TWEAK 
sensitization to TNF  killing requires FADD and is independent of Bax/Bak. The indicated cell lines were treated with 100 ng/ml Fc-TWEAK and/or 100 
ng/ml Fc-TNF  . (E) Loss of cIAP1 or TRAF2 sensitizes immortalized MEFs to TNF  -induced death. MEFs were treated for 24 h with 100 ng/ml Fc-TWEAK 
and/or 100 ng/ml Fc-TNF  . Wild-type MEFs were also treated with 500 nM compound A with or without 100 ng/ml TNF  . Cell death was measured as 
in A. All errors bars represent SEM of at least three independent experiments. Molecular mass is indicated in kD on the left of the autoradiograph. 
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TNF  when the two cytokines are added simultaneously. Consis-
tent with this data, pretreating wild-type MEFs with either TNF  
or TWEAK alone for 24 h before cotreatment with TWEAK/
TNF  or compound A/TNF  did not change the amount of cell 
death observed when cells were cotreated for the same time pe-
riod (Fig. S5 B). This suggests that the prosurvival signals elicited 
by TNF  , such as NF-  B – induced gene transcription, are not 
suffi cient to counteract TWEAK/TNF  killing. 
 TWEAK/TNF  treatment distinguishes 
between normal and transformed cells 
 Genetic knockout cIAP1 mice display no obvious phenotypic 
defects in apoptotic signaling ( Conze et al., 2005 ; unpublished 
data), raising the possibility that primary cells may be less sen-
sitive to TWEAK/TNF  -induced death. Consistent with this 
possibility, primary MEFs showed only a twofold increase in 
death after TWEAK/TNF  stimulation, whereas a 14-fold in-
crease was observed in SV40 large T immortalized MEFs ( Fig. 
7 A ). [ID]FIG7[/ID] TWEAK-induced loss of cIAP1 – TRAF2 was observed in 
both primary MEFs and transformed MEFs ( Fig. 7 B ), as was 
activation of noncanonical NF-  B ( Fig. 7 B ). Although similar 
levels of FN14 were initially present in both MEF lines, these 
increased dramatically after TWEAK stimulation ( Fig. 7 B ), 
implying that FN14 expression is regulated by TWEAK. 
 Further evidence supporting the observation that 
TWEAK/TNF  kill in a death receptor – dependent pathway 
was obtained using FADD  /  MEFs, as these were com-
pletely resistant to TWEAK/TNF  -induced death ( Fig. 6 D ). 
In contrast, TWEAK/TNF  killing was independent of the 
Bax/Bak-dependent apoptotic pathway, as Bax/Bak double 
knockout MEFs showed a similar TWEAK/TNF  sensitivity 
to wild-type MEFs ( Fig. 6 D ). 
 As expected, cIAP1  /  ( Vince et al., 2007 ), TRAF2  /  , 
and TRAF2/TRAF5   /  double knockout or compound A –
 treated MEFs were all extremely sensitive to killing by TNF  
alone ( Fig. 6 E ;  Tada et al., 2001 ), supporting the hypothesis 
that TWEAK-induced loss of the cIAP1 – TRAF2 complex is 
suffi cient to sensitize MEFs to TNF  killing. Surprisingly, 
cIAP2  /  MEFs were not sensitive to TNF  -mediated cell 
death ( Fig. 6 E ), making it unlikely that cIAP2 has a role in 
TWEAK-mediated sensitization to TNF  . 
 Pretreating wild-type MEFs with TWEAK for 8 h before 
addition of TNF  caused a reduction in the total canonical re-
sponse. However simultaneous treatment with TWEAK/TNF  
resulted in an augmented canonical response (Fig. S5 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200801010/DC1), 
making it unlikely that a reduction in prosurvival NF-kB signal 
from TNF  is the reason for TWEAK-induced sensitization to 
 Figure 7.  TWEAK/TNF   treatment distin-
guishes between normal and transformed cells, 
and TWEAK/TNF  killing is suppressed by el-
evated cIAP1 – TRAF2 levels. (A) Primary MEFs 
are resistant to TWEAK/TNF  -induced death. 
Three primary MEF cell lines derived from 
three separate embryos were treated with 100 
ng/ml Fc-TWEAK and/or 100 ng/ml Fc-TNF  
for 24 h, and the amount of cell death was 
measured by propidium iodide staining and 
ﬂ ow cytometry. Error bars are SEM of three 
to ﬁ ve independent experiments. (B) TWEAK 
increases FN14 expression and induces 
cIAP1 – TRAF2 degradation in primary and 
transformed MEFs. Primary MEFs or SV40T 
transformed MEFs were treated with 100 ng/
ml Fc-TWEAK for the indicated times, and DISC 
lysates were analyzed by Western blot. (C) 
PIL2 cells or PIL4 cells were treated with 100 
ng/ml Fc-TWEAK and/or 100 ng/ml Fc-TNF  
for 24 h and cell death was analyzed as in A. 
Error bars are SEM of three independent ex-
periments. (D) Fluorescence microscopy. Bars, 
20  μ m. (E) Enhanced cIAP1 and TRAF2 levels 
in PIL2 cells are resistant to TWEAK-induced 
degradation. PIL2 and PIL4 cells were treated 
with 100 ng/ml Fc-TWEAK for the indicated 
times and lysates were analyzed by Western 
blot. Molecular mass is indicated in kD on the 
left of the autoradiograph. 
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complex to lysosomes and subsequent degradation. In cell lines 
that can be killed by TWEAK, NF-  B induces production of 
TNF  and simultaneously sensitizes tumor cells to TNF-R1 – in-
duced death. Transformation of MEFs renders these cells sig-
nifi cantly more sensitive to killing by TWEAK/TNF  than their 
nontransformed progenitors, but tumor cells that express high 
levels of cIAP1 – TRAF2 are comparatively resistant to TWEAK/
TNF  killing ( Fig. 8 ). [ID]FIG8[/ID] 
 Our data demonstrate that tumor cell sensitivity to 
TWEAK correlates with their sensitivity to synthetic IAP an-
tagonists and that the mechanism of tumor cell killing between 
this class of chemical compounds and naturally occurring li-
gand is remarkably similar. Synthetic IAP antagonists target 
cIAP1 and cIAP2 for complete proteasomal degradation 
( Gaither et al., 2007 ;  Varfolomeev et al., 2007 ;  Vince et al., 
2007 ), whereas TWEAK targets a proportion of the cIAP1 –
 TRAF2 complex (presumably the proportion that can be re-
cruited to FN14) for degradation in a lysosomal 
cathepsin-dependent manner. The end result is, however, the 
same, with activation of NF-  B. In sensitive tumor cell lines, 
activated NF-  B drives TNF  production that, in the absence of 
the cIAP1 – TRAF2 complex, kills them. Likewise, both TWEAK 
and synthetic IAP antagonists sensitize tumor cells to exoge-
nously added TNF  by depleting the cIAP1 – TRAF2 complex. 
 TRAF2-mediated loss by CD40 stimulation requires an 
intact ubiquitylation pathway ( Brown et al., 2001, 2002 ). Previ-
ous work has implicated cIAP1 in the ubiquitylation and protea-
somal degradation of TRAF2 by TNF-R2 ( Li et al., 2002 ;  Conze 
et al., 2005 ;  Zhao et al., 2007 ), and cIAP2 can ubiquitylate and 
degrade TRAF1 ( Lee et al., 2004 ). In this context, it was com-
 Because TWEAK-mediated loss of the cIAP1 – TRAF2 
complex is suffi cient to sensitize tumor cells to TNF  -induced 
death, we tested whether a liver progenitor tumor cell line, 
PIL2, which expresses high levels of the cIAP1 – TRAF2 com-
plex ( Fig. 7 E ), was resistant to TWEAK/TNF  killing relative 
to a liver progenitor cell line, PIL4, with lower levels ( Fig. 7 E ). 
Treatment of these cells with TWEAK/TNF  killed  > 90% of 
PIL4 cells, whereas only 35% of PIL2 (cIAP1 high) cells were 
killed ( Fig. 7, C and D ). Western blot analysis showed that PIL2 
and PIL4 cells expressed equal levels of FN14 ( Fig. 7 E ). Sig-
nifi cantly, TWEAK-induced degradation of cIAP1 – TRAF2, 
and increased FN14 levels, were attenuated in the PIL2 cells, 
implying that enhanced expression of cIAP1 – TRAF2 inhibits 
FN14 signaling and counters TWEAK-induced sensitivity to 
TNF  -induced death. 
 Discussion 
 Recent work using synthetic IAP antagonists has shown that 
cIAPs play a pivotal role in regulating NF-  B signaling from 
TNF-R1 ( Gaither et al., 2007 ;  Varfolomeev et al., 2007 ;  Vince 
et al., 2007 ). However, the binding of cIAP1 to TNF receptors 
other than TNF-R1 or TNF-R2, or the physiological regulation 
of cIAP1 by TNF receptor signaling, remains poorly character-
ized. In this paper, we show that when ligated with TWEAK, 
endogenous FN14 recruits a cIAP1 – TRAF2 complex that is 
subsequently degraded by a cathepsin-mediated lysosomal 
pathway. TWEAK/FN14 signaling results in both canonical and 
noncanonical NF-  B activity. Noncanonical NF-  B activity is 
most probably the result of relocalization of the cIAP1 – TRAF2 
 Figure 8.  Model for TWEAK killing. TWEAK 
binding to FN14 induces the recruitment of a 
cIAP1 – TRAF2 complex. This complex is then 
targeted for lysosomal degradation by the 
MVB pathway. The loss of cIAP1 or TRAF2 in-
duces the stabilization of NIK and subsequent 
activation of noncanonical NF-  B. The ca-
nonical NF-  B pathway is also activated in re-
sponse to TWEAK. Activation of NF-  B drives 
autocrine TNF  production in TWEAK-sensitive 
cell lines. The loss of cellular cIAP1 and TRAF2 
by FN14 signaling prevents their recruitment 
to TNF-R1 upon autocrine TNF  binding, and 
this promotes the formation of a death-induc-
ing complex and apoptotic signaling. 
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these cells were highly sensitive to TWEAK/TNF  killing. In 
contrast, the increased levels of cIAP1 – TRAF2 in the tumori-
genic PIL2 cells appeared to block FN14 signaling, as the 
cIAP1 – TRAF2 complex was resistant to TWEAK-induced deg-
radation and the cells were more resistant to TWEAK/TNF  -
induced death. These results are also consistent with our fi ndings 
that the overexpression of cIAP1 and TRAF2 is suffi cient to 
block FN14-induced NF-  B activity. 
 The fact that the cIAP1-cIAP2 locus is amplifi ed in some 
human tumors and a mouse model of liver cancer ( Zender et al., 
2006 ) and that high levels of expression of cIAP1 have been ob-
served in several cancers argues that increased cIAP1 can con-
tribute to oncogenesis. Our results suggest that one possible 
mechanism by which it does this is by regulating the balance 
between life and death signaling from TNFSF receptors. Our 
fi ndings provide further support for using IAP antagonists as 
tumor therapy and extend options by highlighting the fact that 
TWEAK is a physiological regulator of TNFSF signaling that 
targets the cIAP1 – TRAF2 complex rather than the IAPs alone. 
 Materials and methods 
 Cell lines, transient transfections, antibodies, and protease inhibitor 
 SW480, K562, MCF7, BJAB, G401, ColoF, and NIH 3T3 cell lines were 
a gift from L. O ’ Reilly (The Walter and Eliza Hall Institute, Melbourne, Aus-
tralia;  O ’ Reilly et al., 2000, 2002 ), RM, WW, and A2058 were a gift 
from P. Hersey (Calvary Mater Newcastle Hospital, Newcastle, Australia; 
 Zhang et al., 1999 ), and HT29, SKOV3, OVCAR4, and MDAMB231 
were purchased from American Type Culture Collection. Kym1 cells were 
a gift from M. Grell (ICBI, Stuttgart, Germany;  Grell et al., 1999 ). D2234 
and D2247 early passage lines were derived from specimens obtained 
from patients who had undergone tumor resection at Duke University Hos-
pital (Durham, NC;  Ashley et al., 2008 ). Transient transfections (typically 
using 1  μ g of plasmid DNA per 10-cm plate of cells) were performed with 
effectene as described by the manufacturer (QIAGEN). Antibodies used in 
this study for ﬂ ow cytometry were anti-FN14 (Abcam), Goat anti – mouse 
RPE (Millipore), and Goat anti – human RPE (SouthernBiotech). Antibodies 
used for Western blots were Goat anti – human IgG HRP (Jackson Immu-
noResearch Laboratories), anti-cIAP1 (in house), anti-TRAF2 (Santa Cruz 
Biotechnology, Inc.), anti-FN14 (Cell Signaling Technology), anti-NIK (Cell 
Signaling Technology), anti – phospho – NF-  B (Ser536) p65 (Cell Signaling 
Technology), anti-I  B, (Cell Signaling Technology), anti – phospho-I  B 
(Ser32/36; Cell Signaling Technology), anti – NF-  B p65 (Santa Cruz), 
anti – NF-  B2 (Cell Signaling Technology), anti – NF-  B p50 (Santa Cruz), 
anti –  -actin (Sigma-Aldrich), anti-ubiquitin (Cell Signaling Technology), 
anti-TRAF3 (BD Biosciences), anti – FLAG M2 (Sigma-Aldrich), anti – IgG bio-
tin (Jackson ImmunoResearch Laboratories), and anti-VSV (MBL Interna-
tional). Protease inhibitor cocktail ﬁ nal concentrations were the following: 
AEBSF, 1.3 mM; aprotinin 1.1  μ M; bestatin, 66  μ M; E-64, 20  μ M; leu-
peptin, 27  μ M; and pepstatin A, 13  μ M. 
 Cell culture and lentivirus production 
 All cell lines were maintained in DME supplemented with 10% FCS, 2 mM 
L- glutamine, and penicillin/streptomycin and grown at 37 ° C in 10% CO 2 . 
PIL2, PIL4, and BMOL liver progenitor cells were maintained in Williams 
Media E supplemented with 2 mM L- glutamine, penicillin/streptomycin, 20 
ng/ml mouse EGF, 30 ng/ml human IGF II, and 0.25 U/ml human insulin 
and grown at 37 ° C in 5% CO 2 . 
 To generate lentiviral particles, 293T cells were transfected with 
packaging constructs pCMV  ð R8.2, VSVg, and the relevant lentiviral 
plasmid in the ratio of 1:0.4:0.6. After 24 – 48 h, 0.45  μ M of the virus-
containing supernatants were harvested and ﬁ ltered. 12  μ g/ml Polybrene 
was added and target cells were infected with virus supernatant for 24 –
 48 h. The media was subsequently changed and successful infection se-
lected for with 2 – 5  μ g/ml puromycin (pF 5xUAS selection) or 100 – 500 
 μ g/ml hygromycin B (GEV16 selection) or by screening for GFP ﬂ uores-
cence (pTRH). pF 5xUAS-inducible constructs were induced with 100 nM 
4-hydroxy tamoxifen for 16 h before harvesting lysates for Western blot-
[AQ2]
pletely unexpected that inhibition of the proteasome did not pre-
vent TWEAK/FN14-mediated loss of cIAP1 – TRAF2, although 
TRAF2 depletion required cIAP1 function. However, TWEAK/
FN14-induced cIAP1 – TRAF2 degradation was prevented by 
several different classes of inhibitors of lysosome proteases or 
function and could be specifi cally blocked by an inhibitor of the 
lysosome cysteine protease cathepsin B. Consistent with this 
observation, TWEAK mediated relocalization of TRAF2 to 
punctate vesicles that often overlapped with, and were in con-
tact with, lysotracker-stained vesicles. 
 Given previous reports implicating the proteasome in 
TRAF2 degradation, it remains unclear whether other TNFSF 
ligands can also stimulate cIAP1 – TRAF2 loss through lyso-
somal mechanisms. However, it has been demonstrated that 
CD30-induced TRAF2 degradation was blocked by nonprotea-
somal inhibitors ( Duckett and Thompson, 1997 ). It is likely that 
lysosomal degradation of the cIAP1 – TRAF2 complex occurs 
by the well documented multivesicular body (MVB) pathway, 
whereby endocytosed cell surface material is further internal-
ized to form endosomal MVBs, which subsequently fuse with 
lysosomes ( Fig. 8 ;  Williams and Urb é , 2007 ). The fi nding that 
cIAP1 was required for TRAF2 degradation raises the possibil-
ity that cIAP1-mediated ubiquitylation of TRAF2/FN14 targets 
the FN14 complex to the MVB pathway, as has previously been 
demonstrated for ubiquitin-dependent MVB targeting of several 
cell surface receptors. Depletion of cIAP1 – TRAF2 by TWEAK/
FN14 is the most likely cause of noncanonical NF-  B activa-
tion. Both cIAP1 and TRAF2 are required to inhibit noncanoni-
cal NF-  B activation from TNF receptors, and genetic knockout 
of either component alone results in spontaneous noncanonical 
NF-  B activity. Underlining the requirement for their concerted 
action, overexpression of either cIAP1 or TRAF2 alone does 
not affect FN14 signaling, but overexpression of both compo-
nents is able to block TWEAK-induced NF-  B. 
 The NF-  B activity observed after FN14 signaling re-
sulted in an increase in production of TNF  in TWEAK-sensi-
tive cells but not in TWEAK-resistant cells. TWEAK-resistant 
cell lines were nevertheless sensitized to exogenously added 
TNF  , emphasizing that it is the production of autocrine TNF  
that determines sensitivity of cells to TWEAK. This fi nding is 
consistent with previous observations that activation of TNF-
R2, CD30, or CD40 can also induce TNF  and enhance TNF-
R1 apoptotic signaling ( Grell et al., 1999 ). 
 We demonstrated TWEAK binding and FN14 expression 
on both primary and tumor cells in culture. Surprisingly, how-
ever, primary nontransformed MEFs were insensitive to 
TWEAK/TNF  -induced death, whereas the same MEFs trans-
formed by SV40 Large T were effi ciently killed by this treat-
ment. It is not clear why tumor cells show heightened sensitivity 
to TWEAK/TNF  -induced apoptosis, as TWEAK stimulation 
of primary MEFs still resulted in the loss of cIAP1 – TRAF2 and 
NF-  B activation. 
 Not all tumor cell lines were sensitive to TWEAK/TNF  
treatment. In particular, PIL2 liver progenitor oval cells that ex-
press much higher levels of cIAP1 and TRAF2 than PIL4 cells 
were resistant to TWEAK/TNF  -induced death. TWEAK stim-
ulation of PIL4 cells resulted in the loss of cIAP1 – TRAF2, and 
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 Nuclear fractionation 
 Cells were harvested, washed in PBS, and resuspended in lysis buffer (10 
mM hepes-KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl, 0.5 mM DTT, and 
protease inhibitor cocktail) and incubated on ice for 15 min. The lysis 
buffer was adjusted to 0.6% NP-40 and immediately vortexed for 10 s, 
and the pellet (membrane) and supernatant (cytosol) fractions were sepa-
rated by centrifugation at 14,500  g for 5 min. Equal amounts of mem-
brane (nuclear) and cytosolic fractions were analyzed by SDS-PAGE and 
Western blotting. 
 ELISA assays 
 Cells were grown on 10-cm plates, harvested, washed thoroughly with 
ice-cold PBS, and lysed in 300  μ l DISC buffer for 20 min on ice. Cell ly-
sate was spun for 10 min at 14000  g , and the soluble material was col-
lected. Alternatively, the cell supernatant from the same plates was 
collected and ﬁ ltered to remove cellular debris. Soluble cell lysate or the 
ﬁ ltered cell supernatant was used for human or mouse TNF-  ELISA as-
says (mouse; HSTA00C; R & D Systems) according to the manufacturer ’ s 
protocol. Protein from the cell lysate was quantiﬁ ed using the BCA assay 
(Thermo Fisher Scientiﬁ c). 
 Immunoﬂ uorescence, image acquisition, and processing 
 D645 cells grown on glass coverslips were ﬁ xed with 3.2% PFA for 20 
min, washed in PBS, and permeabilized with 0.5% Triton X-100 for 5 
min. Cells were blocked, incubated with primary antibody, washed four 
times with PBS, and then incubated with anti – rat or anti – mouse Alexa 
Fluor 488 – conjugated secondary antibody (Invitrogen) and washed four 
times again. All blocking steps and antibody incubations were performed 
with PBS containing 1% BSA for 30 min. The primary antibodies used 
were anti-FLAG (Amrad) or anti-TRAF2 (BD Biosciences). Cells were 
viewed on an inverted confocal microscope (TCS-SP2; Leica) using a 63 × 
1.4 NA oil immersion objective at room temperature. Images were col-
lected and analyzed with SP2 imaging software (Leica) or ImageJ soft-
ware (National Institutes of Health; http://rsb.info.nih.gov/ij). All images 
were in TIF format and imported into Freehand MX (Macromedia) for the 
compilation of ﬁ gures. 
 Online supplemental material 
 Fig. S1 shows that Fc-TWEAK binds to a large selection of adherent trans-
formed cell lines. Fig. S2 shows analysis of TWEAK-induced cIAP1 – TRAF2 
degradation. Fig. S3 shows that oss of cIAP1 or TRAF2 results in constitu-
tive activation of noncanonical NF-  B pathway and that an I  B superrepres-
sor blocks TWEAK-induced NF-  B activity. Fig. S4 shows that inhibition of 
TNF  signaling or NF-  B activity provides clonogenic protection to TWEAK-
treated cells. Fig. S5 shows the response of wild-type and knockout MEFs 
to TWEAK and TNF  treatment. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200801010/DC1. 
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ting or before death assays. Flp In T-Rex 293 cells (Invitrogen) containing 
doxycycline-inducible VSV-tagged FN14 were generated according to 
the manufacturer ’ s instructions. 
 Constructs 
 The NF-  B lentiviral reporter vector pTRH1 mCMV NF-  B dscGFP was pur-
chased from System Biosciences. Cre recombinase and SV40 Large T anti-
gen were cloned into the lentiviral vector pFU. In the inducible lentiviral 
system, the inducible transcriptional activator Gal4 1 – 147 ER T2 VP16 
(GEV16) was cloned into pFU PGK Hygro, and the genes dnTNF-R2, dn-
TRAIL-R2 or dnCD27 ( Bossen et al., 2006 ), I  B SR super repressor ( Van Ant-
werp et al., 1996 ), and N-Flag crmA, were cloned into a pF 5xUAS SV40 
Puro vector. D. Baltimore provided us with pFU and lentiviral packaging 
constructs and T. Mantamadiotis (Monash University, Melbourne, Austra-
lia) provided the ERT2 construct. Complete sequence of all constructs can 
be obtained upon request. 
 Generation of MEFs 
 Knockout MEFs were generated from embryonic day – 15 embryos from 
wild-type and XIAP  /  mice using standard procedures and infected with 
SV40 Large T antigen-expressing lentivirus. cIAP1, cIAP2, or TRAF2 condi-
tional knockout MEFs were similarly generated from cIAP1 LoxP/LoxP or 
TRAF2 LoxP/LoxP embryonic day – 15 embryos. To delete cIAP1 or TRAF2, 
the transformed MEFs were infected with a cre-expressing lentivirus (pFU 
cre SV40 puro), and deletion was conﬁ rmed by PCR and Western blotting. 
To delete cIAP2, the transformed MEFs were infected with a FlpE-express-
ing lentivirus (pFU FlpE PGK Hygro). W.-C. Yeh (University of Toronto, To-
ronto, Canada) provided FADD knockout MEFs, H. Nakano (Juntendo 
University, Tokyo, Japan) provided TRAF2/TRAF5 double knockout MEFs, 
and D. Huang (The Walter and Eliza Hall Institute, Melbourne, Australia) 
provided Bax/Bak double knockout MEFs. 
 Immunoﬂ ow cytometry 
 Approximately 3  × 10 6 cells were harvested, washed in PBS, and resus-
pended in buffer (KDS/BSS containing 3% FCS) on ice. 500 ng Fc-TWEAK 
or 1  μ g FN14 antibody was incubated with cells on ice for 20 min, and 
then the cells were washed and incubated with anti – human IgG biotin for 
20 min on ice, followed by Streptavidin Tri-color biotin (for Fc-TWEAK 
staining) or anti – mouse IgG-RPE (for anti-FN14 staining). Cells were 
washed and then analyzed by ﬂ ow cytometry. 
 Death assays 
 Cells were seeded on 12-well tissue culture plates at   40% conﬂ uency and 
were allowed to adhere for 16 – 20 h. Compound A (5 nM Kym1 cells or 
500 nM of all other cell types), 70 ng/ml of human Fc-TNF  , or 100 ng/ml 
of human Fc-TWEAK were added to cells for 24 or 48 h, and cell death 
was measured by propidium iodide staining and ﬂ ow cytometry. In each 
sample, 10,000 events were measured and the cell death (percentage of 
propidium iodide-positive cells) was quantiﬁ ed. 
 Western blotting and immunoprecipitations 
 For immunoprecipitation of endogenous FN14, cells were grown on 15-cm 
tissue culture plates and, when approaching conﬂ uency, were harvested 
and resuspended in 800  μ l of ice-cold DME. 1.6  μ g Fc-TWEAK was added 
for 30 min on ice (or indicated times) at 37 ° C. Cells were subsequently 
washed in ice-cold PBS and lysed in DISC buffer (1% Triton X-100, 10% 
glycerol, 150 mM NaCl, 20 mM Tris, pH 7.5, 2 mM EDTA, and complete 
protease inhibitor cocktail [Roche]) on ice. Cell lysate was spun at 14,000 
 g for 10 min, and the soluble material was precleared with Sepharose 6B 
beads at 4 ° C for 1 h. Fc-TWEAK – bound material was immunoprecipitated 
by adding the precleared lysate to EZI view Protein A – agarose (Sigma-Al-
drich) for 1 – 2 h at 4 ° C. Samples were washed four times with DISC buffer 
and then eluted with 1% SDS and   -mercaptoethanol at 95 ° C for 3 min. 
Samples were separated on 4 – 20 (Bio-Rad Laboratories) or 4 – 12% (Invit-
rogen) polyacrylamide gels and transferred to nitrocellulose membranes 
for antibody detection. All membrane-blocking steps and antibody dilu-
tions were performed with 5% skim milk in PTBS (PBS containing 0.1% 
Tween 20), and washing steps were performed with PTBS. Proteins on 
Western blots were visualized by ECL (GE Healthcare) after incubation of 
membranes with HRP-coupled secondary antibodies. 
 Immunoprecipitation of FLAG-tagged cIAP1 constructs or VSV-
tagged FN14 were performed similarly, except one 10-cm plate of cells 
was used per immunoprecipitation, and anti – FLAG M2 – conjugated aga-
rose (Sigma-Aldrich) or anti – VSV-conjugated agarose (Sigma-Aldrich) were 
used for immunoprecipitation of the relevant proteins. 
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